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Abstract Alzheimer’s disease (AD) is associated with
cognitive and functional impairment as well as neuropsy-
chiatric sequelae, including psychotic symptoms such as
delusions and hallucinations. Strong evidence supports the
need to study delusions separate from hallucinations.
Integrating the epidemiology, clinical correlates, and neu-
ropathological and genetic literature for delusions in AD
allows us to speculate on etiology and mechanisms. Plaque
and tangle deposition in individuals with susceptible alleles
of serotonergic, muscarinic, nicotinic, or Apoε4 genes
appears to result in disruption of cortical circuitry, culmi-
nating in delusions. While delusions in AD correspond to a
phenotype distinct from AD without delusions, subtypes of
delusions may also define further distinct clinical entities.
Persecutory delusions may occur earlier in the illness and
have a more significant genetic component than misiden-
tification delusions, which are associated with increased
cognitive impairment and advanced dementia. Clearly
distinguishing between these two syndromes is essential
to making progress in the area of delusions in AD.
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Introduction
Despite being considered a disorder of cognition, Alzheimer’s
disease (AD) is associated with many neuropsychiatric
symptoms (NPS) of clinical significance. NPS, also called
behavioral and psychological symptoms of dementia (BPSD),
are present in up to 97% of people diagnosed with dementia,
resulting in suffering, caregiver distress, and extensive
resource utilization [1]. These noncognitive manifestations
of dementia are the primary reason for transfer of patients
with dementia from general hospitals to psychiatric hospitals,
and for their institutionalization out of the community [2]. Of
these NPS, psychosis is prominent and consists of halluci-
nations and delusions. Hallucinations are perceptions in the
absence of a stimulus, whereas delusions are fixed false
beliefs that are neither amenable to reason nor consistent
with cultural beliefs. This review focuses on research reports
in which delusions in AD (AD+D) can be discussed
separately from psychosis in AD (AD+P) in general, or in
which the discussion of AD+P is instructive to the
understanding of AD+D.
The index patient of Alois Alzheimer [3] suffered from
paranoid delusions that were a prominent part of her illness.
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Delusions in AD disease may have varying content,
including delusions of persecution, theft, infidelity, aban-
donment, or that the patient’s deceased loved ones are still
living, as well as misidentification syndromes (MIS) [4].
Misidentification delusions frequently seen in AD often
represent true neuropsychiatric manifestations of neuro-
degeneration and include Capgras type (the feeling that
someone known to the patient is replaced by an impostor),
phantom boarder syndrome (the feeling that strangers are
living in the patient’s house), mirror sign (patient misiden-
tification of his or her own image in a mirror), and TV sign
(television images misidentified as real) [5]. Despite the
longstanding recognition that delusions are part of AD, our
understanding of the pathophysiology and pharmacotherapy
of delusions is still incomplete. The aim of this review is to
reconcile the clinical presentation with the neurobiological
underpinnings of AD+D with a focus on neuropathology
and genetics in order to better guide future investigation
and treatment.
Phenomenology
Strict diagnostic criteria for AD+P, written in the DSM-IV
format, have been proposed by Jeste and Finkel [6] and
include the presence of delusions or hallucinations (auditory
or visual) in the context of clinically diagnosed AD.
Psychotic symptoms must not predate the onset of the
dementia so that a prior history of a primary psychotic
disorder such as schizophrenia, schizoaffective disorder,
delusional disorder, or mood disorder with psychotic features
must be ruled out. Similarly, psychotic symptoms presenting
in the context of delirium or resulting from a general medical
illness or the use of drugs or other substances are excluded
from this proposed diagnostic category. This construct has
been validated by Schneider and colleagues [7] in a
reanalysis of a risperidone clinical trial in which the
Behavioral Pathology in Alzheimer’s Disease rating scale
was used to capture delusions (mostly persecutory type) and
hallucinations (of all types) persisting over 2 to 4 weeks. Of
the 625 patients enrolled in the original trial for behavioral
issues, 75% met the criteria for AD+P. Thus, while over-
lapping with agitation or aggression, AD+P was a discrete
clinical entity with patient demographics differing from the
demographics of nonpsychotic patients with AD (AD-P).
However, the breakdown between delusions and hallucina-
tions was not reported.
An alternative set of “Alzheimer-associated psychotic
disorder” criteria using a syndromic approach to taxonomy
has been suggested by Lyketsos and colleagues [8]. In this
construct, discrete affective and psychotic syndromes of AD
have been delineated [8] and validated [9]. In a consecutive
series of 771 patients with probable AD, delusions diagnosed
with the Psychosis Dementia Scale within the previous
4 weeks were subclassified into paranoid/misidentification
and expansive domains. Although 33% of patients had
delusions, only 7% of them had hallucinations, most of
whom also had delusions.
A contrasting approach to that of Lyketsos et al. [8] is
used by Cook and colleagues [10]. They identified and
classified AD+P subtypes based on the presence of
individual psychotic symptoms in isolation from other
behavioral symptoms. In a cross-sectional study of 188
possible and probable AD patients, factor and cluster
analysis of Behavioral Rating Scale items identified 2
separate factors: a misidentification/hallucination factor
(including symptoms of simple and delusional misidentifi-
cations and hallucinations) and a persecutory delusion
factor. Subsequent analysis by the same group has
demonstrated that impairment in verbal fluency and
visuospatial function is restricted to the misidentification/
hallucination subtype, that the paranoid subtype does not
differ from nonpsychotic AD patients on cognitive meas-
ures, and the ability to detect meaningful biologic associ-
ations of AD+P would be enhanced by separate analyses of
the misidentification and paranoid delusional phenotypes
[11]. These results were consistent with the study of Forstl
and colleagues [12] that found that delusions of misiden-
tification were associated with greater cognitive impairment
than the absence of delusions in a sample of patients with
moderate to severe AD.
Epidemiology and Risk Factors
The results of epidemiologic studies of psychosis in
dementia have been variable given the heterogeneity of
the study group. A systematic review by Ropacki and Jeste
[13] reported that 41% of patients with AD experience
psychosis, including 23% with delusions, 5% with halluci-
nations, and 13% with both. The most common type of
delusion is delusion of theft. In this review, AD+P was
associated with a more rapid cognitive decline, and its
incidence increased progressively over the first 3 years of
the illness, with a subsequent plateau. Inadvertent inclusion
of patients with Lewy body dementia and poor recollection
of family history is considered a confound in these
epidemiologic studies (as is the common failure to separate
delusions from hallucinations). A more recent study
conducted by Weamer and colleagues [14] assessed 361
patients diagnosed with possible or probable AD or mild
cognitive impairment without psychosis at baseline.
Patients were observed longitudinally until study comple-
tion, loss to follow-up, or until the patient became too
impaired to return to the clinic for reassessment. Neurolog-
ical evaluation, cognitive testing with the Mini-Mental State
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Examination (MMSE), and diagnostic re-evaluation (in-
cluding assessment for the presence of psychosis) were
conducted on an annual basis. AD+P was observed in 122
(34%) patients during the follow-up period. Global cogni-
tive impairment (ie, the MMSE score) was the only
baseline variable consistently associated with a reduced
time to onset of psychosis, especially in those with early- to
mid-stage disease. Unfortunately, despite a useful longitu-
dinal approach, psychosis was not described in terms of its
components, limiting the utility of this study in contributing
to the understanding of the neurobiology of delusions. Very
recently, in a cross-sectional sample of much older adults
with AD (>85 years of age), Ostling and colleagues [15]
reported that 22% had delusions and 30% had hallucina-
tions. Although psychosis in general and hallucinations
increased with dementia severity, no statistically significant
association was found between delusions and dementia
severity. This highlights the importance of separating
delusions and hallucinations when studying the evolution
of these symptoms in AD.
The Cache County Dementia Prevalence study determined
prevalence of NPS over a mean and median 5-year follow-up
period after diagnosis in a sample with a mean duration of
dementia of 2 years at baseline [1]. Point prevalence for
delusions was 18% at baseline and 34% to 38% during the
past three yearly visits; for hallucinations, it was 10% at
baseline and 19% to 24% thereafter. Period prevalence over
the 5-year follow-up period was 60% for delusions and 38%
for hallucinations. Gauthier and colleagues [16] reviewed the
frequency of NPS in samples assessed with the Neuropsy-
chiatric Inventory in three European studies: the Maastricht
Study of Behavior in Dementia; the Réseaux Alzheimer
Français; and the European Alzheimer Disease Consortium.
Delusions occurred in 22% and hallucinations in 9% of
these community samples. Sweet and colleagues [17]
assessed the types of delusions present in individuals
involved in the National Institute of Aging Late Onset AD
Family Study. Among 478 unique participants having
completed at least 1 behavioral assessment, psychotic
symptoms were present in 239 (50%). The most common
psychotic symptoms were delusional misidentification of
people (23%), paranoia (21%), and believing that dead
people were still alive (19%).
A large study by Harciarek and Kertesz [18] investigated
the prevalence of MIS in 392 individuals with probable AD
determined by a semistructured interview of patients and
reliable caregivers. MIS were identified in 16% of
participants. The most frequent form of MIS were Capgras
delusions, often accompanied by reduplication of place,
phantom boarder phenomenon, or both. As part of the
Medical Research Council Cognitive Function and Aging
study, Savva and colleagues [19•] determined the preva-
lence and correlates of NPS in a cohort of 587 participants
with dementia, and assessed subtypes of AD+D. At
baseline, persecutory beliefs were held by 25% of individ-
uals and misidentifications by 20%. At 2-year follow-up,
the incidence of new misidentifications was higher than that
of new persecutory delusions. A factor analysis revealed a
four-factor solution, with persecutory delusions and mis-
identifications best fit on separate factors, again supporting
the idea that these two types of delusions are separate
phenomena with separate trajectories and possibly separate
neurobiological underpinnings.
It can be difficult to differentiate between a true delusion
and a belief that is secondary to other cognitive difficulties
(eg, misplacing personal belongings and concluding that
the items were stolen, or confabulating a story to make
sense of one’s confusing experience). This is particularly
the case given that severity of cognitive dysfunction has
been shown to be a strong predictor of AD+P [14, 20].
However, in the descriptive analysis of the randomized
VISTA (Video-Imaging Synthesis of Treating Alzheimer’s
Disease) trial [21], misplacements were distinguished from
delusions, with 51% of patients with AD and misplace-
ments not having delusions. In the 49% of patients with AD
and misplacements who had delusions, 36% were delusions
of theft. A recent Japanese study assessed the prevalence
and risk factors for delusions of theft in a sample of 56 AD
patients: 25% of patients had delusions of theft, and these
were associated with female gender, absence of cohabiting
family members, neurotic personality, and retained social
cognitive function [22].
Frontal impairment as measured by the Frontal Assess-
ment Battery (FAB) has been associated with AD+D in
general and persecutory delusions in particular. Nagata and
colleagues [23••] examined the relationship between perse-
cutory delusions and frontal lobe function using the
Japanese version of the FAB. A total of 48 probable AD
patients (MMSE≥18 and Clinical Dementia Rating of 0.5
or 1.0) were divided into two groups: AD+D and AD
without delusions (AD-D). The groups did not differ
significantly with regard to sex, age, duration of illness,
education, or MMSE scores. However, mean (+SD) FAB
scores were significantly different between the two groups
(AD+D, 11.6+2.8; AD-D, 13.9+2.5). Logistic regression
showed that the FAB scores, but not the MMSE scores,
were associated with persecutory delusions. In contrast,
frontal executive functioning was not associated with
confabulations in a sample of 22 probable AD patients
with confabulation compared with 22 matched controls
[24]. These findings implicate frontal lobe impairment
specifically, and separately from global cognitive impair-
ment in the presence of persecutory AD+D (and not
confabulation), and emphasize the need to evaluate cogni-
tion more closely in determining the association between
cognition and delusional subtypes.
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Delusions also have been shown to have an impact on
real world functioning in AD. A recent review by Fischer
and colleagues [25] showed that delusions are associated
with reduced functional performance in patients with AD.
The authors commented that studies conducted to date
likely have underestimated the impact of delusions on daily
functioning. This is due to an overreliance on functional
assessment scales of basic versus instrumental activities of
daily living, the use of crude assessments of cognition, and
the lack of longitudinal assessments.
Neuropathology
Several postmortem and imaging studies have attempted to
elucidate the neuropathology and neurochemistry of delusions
in dementia. Using 27 autopsy-confirmed AD cases, Zubenko
and colleagues [26] found that psychosis was associated with
a significantly increased density of senile plaques and
neurofibrillary tangles in the prosubiculum and middle
frontal cortex, and found trends toward increases in the
superior temporal and entorhinal cortices. Psychosis was also
associated with the relative preservation of norepinephrine in
the substantia nigra and a significant reduction in serotonin
in the prosubiculum, with trends toward serotonin reduction
in the middle frontal gyrus, superior temporal cortex,
entorhinal cortex, substantia nigra, thalamus, amygdala, and
caudate nucleus. Psychosis was not divided into delusions
and hallucinations, limiting the interpretation of these data
specifically for delusions.
Subsequently, Förstl and colleagues [27] investigated 56
patients with definite AD and focused on delusional
subtypes. Misidentifications were associated with lower
neuron counts in the area CA1 of the hippocampus, while
paranoid delusions were observed in patients with less severe
cell loss in the parahippocampal gyrus but with lower cell
counts in the serotonergic dorsal raphe nucleus. Mukaetova-
Ladinska and colleagues [28] reported that a positive history
of misidentification delusions is related to an increased
density of neuritic plaques in fronto-parieto-occipital lobes.
Farber and colleagues [29] observed 109 patients with AD
and after their death compared the pathology in those with
and without psychosis. Delusions occurred in almost all
patients with psychosis (94%), and hallucinations in the
absence of delusions were very rare (6%). Suspiciousness
was the most common delusion, present in 62%, with
misidentifications present in 43%. Although there were no
differences in total senile plaques or cored senile plaques, a
greater density of neocortical neurofibrillary tangles was
found in AD+D as compared with AD-D. This increase was
independent of dementia severity.
Lai and colleagues [30] used postmortem radioligand
binding assays to quantify muscarinic receptors in AD
patients. Overall, there was a decrease in M2 density in the
frontal lobes of patients with AD compared with controls.
Within the group of AD patients, M2 receptor density was
higher in Brodmann area 11 (orbitofrontal cortex) of the
patients with delusions than in those without delusions. A
postmortem magnetic resonance spectroscopy study identi-
fied markers suggesting greater neuropil disruption in the
dorsolateral prefrontal cortex, superior temporal gyrus, and
inferior parietal cortex in AD+P compared with AD-P
patients [31]. One can speculate that this greater disruption
represents an acceleration of AD-related neurodegeneration.
Proton magnetic resonance spectroscopy also allows the
indirect measurement of AD pathology in living patients
and has been used to implicate the anterior cingulate cortex
(ACC) in patients with mild AD and delusions compared
with those without delusions [32]. Delusional thinking was
assessed in 30 AD patients using the BEHAVE-AD (Behav-
ioral Pathology in Alzheimer’s Disease) scale, and compared
with AD-D patients (n=22), AD+D patients (n=8) had
Genetics
Although there is clear evidence for the heritability of AD+P
[17], there is also evidence that AD+D specifically is a
heritable trait. Familial aggregation studies of probands and
siblings with AD have shown a higher chance of concor-
dance for AD+D in siblings and probands than by chance
alone [33]. Using genome scans of 148 AD pedigrees,
Avramopoulos and colleagues [34] identified a locus on
chromosome 2p that is linked with AD+D and a locus on
14q that predisposes individuals to a form of dementia
without comorbid psychotic features.
The role of ApolipoproteinE ε4 (Apoε4) in AD+P is
unclear due to conflicting studies using varying methodol-
ogies [35]. When addressing delusions specifically, there is
evidence supporting the role of Apoε4 in predicting AD+D.
In a study of 158 patients with AD, delusions correlated
with number of Apoε4 alleles [36]. In a prospective study
of 87 patients with AD, the number of Apoε4 alleles was
predictive of delusions, with 1 allele carrying a 2.5-fold risk
and 2 alleles a 5.6-fold risk [37]. In another longitudinal
study of 151 AD patients of all severities observed in a
memory clinic, the presence of at least one Apoε4 allele
conferred increased hazard ratios for the development of
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significantly decreased N-acetylaspartate/creatine ratio
(a marker of neuronal density, decreased in AD) and
increased myo-inositol/creatine ratio (an early marker of
AD) in the ACC. Of importance in this study was the finding
that these markers were unrelated to cognition, thus
implicating early and distinct neuropathology in the ACC
in the development of psychosis. The distribution of
persecutory and misidentification delusions was not reported.
delusions (3.4-fold) and hallucinations (19.0-fold) [38]. In a
sample of 171 patients with late-onset AD consecutively
admitted to a memory clinic, the presence of at least one
Apoε4 allele significantly increased the risk of developing
delusions in the early stage of the illness compared with the
absence of this allele. This association did not hold for
hallucinations or psychosis in general [39]. In a study
looking at 110 AD patients, the number of Apoε4 alleles
has been associated with prevalence and severity of
delusions in AD, with homozygosity conferring the greatest
delusional burden [40]. In a large independent cohort of 388
patients with longitudinal measures of NPS, the ε3/ε3
genotype of the ApolipoproteinE gene was negatively
associated with hallucinations but not significant for delu-
sions, suggesting different genetic determinants for these
separate phenomena [41]. In future studies of AD+D, Apoε4
status, age at onset of illness, and subtype of delusions will
be important factors in characterizing the sample group.
Genes involved in neurotransmitter systems have been
identified as important in the pathogenesis of AD+D. There
is mixed evidence for the serotonin 2A (5HT-2A) receptor
single nucleotide polymorphism 102 T/C. Association
studies have identified the T allele as the risk allele for
AD+D [42]. The T allele also has been associated with a
higher prevalence of delusions and treatment resistance to
second-generation antipsychotics [43]. The C allele has
been found to be protective for delusions [44] but to be the
risk allele for hallucinations in the absence of delusions
[45]. Similarly, with the 5HT-2C single nucleotide
polymorphism Cys23Ser, Ser 23 was found to be the risk
allele for hallucinations in the absence of delusions, and
this effect was additive to 5HT-2A C102 [45]. The serotonin
transporter promoter region (5HT-TPR) also has been
implicated in AD+D. Homozygosity for the long arm leads
to an increase in 5HTT mRNA transcription and 5HT
uptake compared with genes containing at least one short
arm and is protective for AD+D [46]. The dopaminergic
system also has been investigated, with dopamine receptor
DRD3 1/1 allele implicated in delusions compared with the
DRD3 2/2 allele [47]. However, much more work is
required to help us better understand the role of neuro-
transmitter genetics in AD+D.
The idea that so-called psychosis-modifier genes may act
similarly during neurodevelopment to produce schizophre-
nia, or throughout neurodegeneration to produce AD+P was
supported by an investigation of the interleukin (IL)-1β
gene [48]. Functional IL-1β promoter polymorphisms have
been associated with AD+D, leading to speculation that
diminished IL-1β output may promote the psychotic
phenotype through altered neurotransmitter interaction (via
DA or 5HT) or reduced neuronal repair after amyloid-
mediated neurotoxicity. Carson and colleagues [49•] have
investigated genetic variations in the α7 nicotinic receptor
and psychotic symptoms in AD. Sampling 409 individuals
from the Northern Ireland BPSD cohort, an association was
found between the rs6494223 T allele and delusional
symptoms in AD. The frequency of delusional symptoms
was higher in patients homozygous for the T allele
compared with the CC or CT genotypes. This result was
not confounded by MMSE scores. Also of interest was the
location of the single nucleotide polymorphism close to
D15S1360, the dinucleotide repeat polymorphism associated
with schizophrenia. Table 1 summarizes the neuropathological
and genetics findings associated with AD+D. Table 2 reviews
the differences between misidentification and persecutory
delusions in AD.
Discussion
The study of AD+D is an evolving field that is becoming
more refined with time. Historically, AD+D was almost
exclusively discussed within the context of AD+P, but more
literature assessing delusions as separate from hallucina-
tions and assessing subtypes of delusions is emerging.
Understanding the presentation, epidemiology, association
with cognitive impairment in specific domains, and rate of
cognitive decline of persecutory versus misidentification
delusions is essential in understanding the neurobiological
underpinnings of these syndromes. The absence of control-
ling for the confounding factors limits the interpretation of
much of the existing literature.
Neuropathological studies emphasize the important roles
of plaque and tangle density in AD+D, suggesting that frontal
plaques and tangles are associated with delusions. The effect
of these plaques and tangles on neurotransmitter systems may
underscore their role in manifestation of the illness. Seroto-
nergic systems are disrupted in psychosis both cortically and
subcortically and are associated with persecutory delusions
rather than misidentifications. Muscarinic density in the
orbitofrontal cortex also has been linked to AD+D. Further-
more, cortical cell loss is associated with persecutory
delusions, whereas hippocampal cell loss (and thus cognitive
impairment) is associated with misidentifications. The triaxial
inclusion of plaque and tangle density, plaque and tangle
location, and effect on neurotransmitter systems results in a
complicated neuropathological model of AD+D. Difficulty in
controlling for the various permutations and combinations of
these three variables underscores the heterogeneity of data in
this area. Further neuropathological studies with clearly
described clinical samples are warranted.
Genetic studies to date have established strong heritability
for psychosis in AD, suggesting a role for Apoε4 load in
delusional thinking, providing potential links to genes
associated with primary psychotic disorders, and starting to
identify potential neurotransmitter targets for pharmacologic
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intervention. A recent clinical trial demonstrated the efficacy
of citalopram in treating the psychosis of dementia, further
implicating serotonergic mechanisms [50].
Relating the neuropathological and genetic findings using
structural and functional imaging studies holds promise for
the identification of endophenotypes that can then be used in
future mechanistic and pharmacologic studies. Ideally, these
future studies will control for the many variables in the clinical
sample. Practically, however, this is difficult. To further
investigate delusions in dementia, several steps must be
taken. This starts with uniformity in diagnosis. A uniform
standard of qualifying and quantifying AD+D is essential.
Table 2 Differences between misidentification and persecutory delusions in Alzheimer’s disease
Neuropathology Cognition and function
Misidentification
delusions
Lower neuron counts in the area CA1 of
the hippocampus
Greater cognitive impairment at baseline vs AD-D
Increased density of neuritic plaques in the
fronto-parieto-occipital lobes
AD+D patients with hallucinations show greater impairment in verbal fluency
and visuospatial function compared with AD-D patients
Persecutory
delusions
Associated with cortical and subcortical
serotonergic system disruption
Greater frontal impairment measured by the Frontal Assessment Battery (AD
+D, 11.6±2.8; AD-D, 13.9±2.5)
Less severe cell loss in the
parahippocampal gyrus
Frontal Assessment Battery scores significantly influenced by the
manifestation of persecutory delusions
Lower cell counts in the serotonergic
dorsal raphe nucleus
AD+D Alzheimer’s disease with delusions, AD-D Alzheimer’s disease without delusions
Table 1 Summary of neuropathology, genetics, and cognition for Alzheimer’s disease with delusions
Neuropathology Genetics Cognition and function
Alzheimer’s
disease
with
delusions
Greater density of neocortical neurofibrillary
tangles in AD+D compared with AD-D
Higher chance of concordance for AD+D in
siblings and probands
Delusions may be
associated with worse
functional performance
in AD patients
Higher muscarinic receptor (M2) density in the
orbitofrontal cortex (Brodmann area 11) in
AD+D compared with AD-D
Locus on chromosome 2p linked to AD+D
Significantly decreased N-acetylaspartate/cre-
atine ratio and increased myo-inositol/crea-
tine ratio in the anterior cingulate cortex in
AD+D compared with AD-D
Number of Apoε4 alleles predictive of AD+D
(1 allele carrying a 2.5-fold risk and 2 alleles a
5.6-fold risk); also associated with the
prevalence and severity of delusions in AD
Presence of Apoε4 increased hazard ratio for
development of delusions 3.4-fold
For late-onset AD, presence of Apoε4 allele
increased risk of developing delusions in
earlier stage of AD than in patients not
carrying this allele
Homozygosity of Apoε4 alleles associated with
greater delusional burden
Evidence of serotonin 2A receptor single
nucleotide polymorphism 102 T/C; T allele
associated with increased presence of
delusions, while C allele is protective for
delusions
5HT-TPR homozygosity in the long arm is
protective for AD+D as compared with genes
containing at least 1 short arm
α7 nicotinic receptor association between
rs6494223 T allele and delusions in AD;
frequency of delusional symptoms higher in
patients homozygous for the T allele compared
with the CC or CT genotypes
5HT-TPR serotonin transporter promoter region, AD Alzheimer’s disease, AD+D Alzheimer’s disease with delusions, AD-D Alzheimer’s disease
without delusions
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This standard should be valid and reliable and should
specifically characterize the dementia and the delusional
subtypes. Stage and age at onset of dementia are crucial,
as is the duration of delusional thinking. Future studies
should accurately report as much demographic and
clinical data as possible in order to make comparisons
of the literature more valid and further elucidate the
etiopathology of AD+D.
Conclusions
Integrating the epidemiology, clinical correlates, and the
neuropathological and genetic literature in AD+D allows us
to speculate on the etiology and mechanisms of AD+D. Plaque
and tangle deposition in genetically predisposed individuals
with susceptible alleles of serotonergic, muscarinic, nicotinic,
or Apoε4 genes appears to result in disruption of cortical
circuitry, culminating in delusions in the context of AD.
Although delusions in AD seem to correspond to a phenotype
distinct from AD-D, subtypes of delusions may also define
further distinct clinical entities. Persecutory delusions may
occur earlier in the illness and have a more significant genetic
component than misidentification delusions, which are asso-
ciated with increased cognitive impairment and advanced
dementia. Clearly distinguishing between these two syn-
dromes is essential for making progress in the area of AD+D.
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